Completed PHASE3 INTERVENTIONAL 3-arm NCT00147381

Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection

Effectiveness and Safety of Campath-1H as an Induction Agent in Combination With Tacrolimus Monotherapy for Prevention of Graft Rejection Compared to Tacrolimus in Combination With MMF and Steroids in Cadaveric Kidney Transplantation

Sponsor: Astellas Pharma GmbH

Conditions Kidney Transplantation

Interventions Alemtuzumab Tacrolimus

Updated 5 times since 2017 Last updated: Jun 18, 2012 Started: Jan 31, 2004 Primary completion: Aug 31, 2008 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Kidney Transplantation and is currently completed. Astellas Pharma GmbH leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma GmbH
Dr. Claudia Bösmüller

Data source: Medical University Innsbruck

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Innsbruck, Austria